Details of the Drug Reposition

General Information of This Drug (ID: DMU8KOD)

Drug Name
Anakinra   DMU8KOD
Synonyms Kineret; Kineret (TN); Anakinra (USAN/INN)
Therapeutic Class
Antiinflammatory Agents

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Rheumatoid arthritis DISTSB4J FA20 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 3 [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cryopyrin-associated periodic syndrome DISPXXOZ 4A60.1 Discontinued in Phase 3 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
CINCA syndrome DISU6RZC N.A. Investigative [4]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 103950.
2 ClinicalTrials.gov (NCT04364009) Anakinra for COVID-19 Respiratory Symptoms. U.S. National Institutes of Health.
3 Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
4 Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford). 2007 Mar;46(3):473-8.